Breast Cancer Treatment Based on Organ-like Culture

Sponsor
Xijing Hospital
Study ID
NCT03925233
Status
Unknown

Conditions

  • Breast Cancer Organoids

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Trastuzumab — DRUG
    Trastuzumab Injection
  • Doxorubicin Hydrochloride — DRUG
    Doxorubicin Hydrochloride Injection
  • Epirubicin hydrochloride — DRUG
    Epirubicin hydrochloride injection
  • Fluorouracil — DRUG
    Fluorouracil injection
  • Paclitaxel — DRUG
    Paclitaxel injection
  • Gemcitabine — DRUG
    Gemcitabine injection
  • Cisplatin — DRUG
    Cisplatin injection
  • Recombinant Human Endostatin — DRUG
    Recombinant Human Endostatin Injection
  • Pirarubicin hydrochloride — DRUG
    Pirarubicin hydrochloride injection
  • Pyrrolidine — DRUG
    Pyrrolidine tablets
  • Ixabepilone — DRUG
    Ixapilone Injection
  • Tamoxifen citrate — DRUG
    Tamoxifen citrate tablets
  • Vinorelbine tartrate — DRUG
    Vinorelbine tartrate injection
  • Carboplatin — DRUG
    Carboplatin injection
  • Methotrexate — DRUG
    Methotrexate injection
  • Eribulin mesylate — DRUG
    Eribulin mesylate injection
  • Toremifene citrate — DRUG
    Toremifene citrate tablets
  • Anastrozole — DRUG
    Anastrozole tablets
  • Letrozole — DRUG
    Letrozole tablets
  • Exemestane — DRUG
    Exemestane tablets
  • Fulvestrant — DRUG
    Fulvestrant injection
  • Olaparib — DRUG
    Olapani pill
  • Bevacizumab — DRUG
    Bevacizumab injection
  • Apatinib mesylate — DRUG
    Apatinib mesylate tablets
  • Pattozumab — DRUG
    Pattozumab injection
  • Capecitabine — DRUG
    Capecitabine tablets
  • Ear particles — DRUG
    Ear particles
  • Aidi Injection — DRUG
    Aidi Injection
  • Cyclophosphamide — DRUG
    Cyclophosphamide injection

Study Details

Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.

Key Dates

Start date
Jan 2, 2019
Status verified
Mar 2019
Primary completion
Dec 15, 2021
Completion
Dec 15, 2021

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: HER2+ Breast Cancer
  • Arm: ER+ Breast Cancer
  • Arm: Triple Negative Breast Cancer

Primary Outcome Measure

Detection of cell viability [ Time Frame: 8 weeks before neoadjuvant chemotherapy ]